United Therapeutics
UTHR
373 hedge funds and large institutions have $6.69B invested in United Therapeutics in 2015 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 131 increasing their positions, 140 reducing their positions, and 51 closing their positions.
2% less call options, than puts
Call options by funds: $39.1M | Put options by funds: $40M
6% less repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 140
3% less funds holding
Funds holding: 384 → 373 (-11)
20% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 51
25% less capital invested
Capital invested by funds: $8.89B → $6.69B (-$2.2B)
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$118M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$71.7M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$67.1M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$60M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$59.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$195M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$67.4M |
| 3 |
FAM
Fred Alger Management
New York
|
-$48.1M |
| 4 |
PC
PointState Capital
New York
|
-$47.8M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$41.2M |
UTHR Hedge Fund Activity: Q3 2015 in Review
373 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2015, worth a combined $6.69B — down 25% from $8.89B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of UTHR and 41 opened new positions — a net loss of 10 holders — while 140 trimmed existing stakes and 131 added.
The largest buyer was Scopia Capital Management, adding an estimated $118M. The largest seller was LSV Asset Management, cutting an estimated $195M.
- 373 institutional investors held United Therapeutics (UTHR) as of Q3 2015, down from 384 in Q2 2015.
- Funds reported $6.69B of United Therapeutics stock for Q3 2015, down 25% quarter-over-quarter.
- 41 funds opened new United Therapeutics positions in Q3 2015 and 51 closed out, a net change of -10 holders.
- The largest United Therapeutics buyer in Q3 2015 was Scopia Capital Management, an estimated $118M added.
- The largest United Therapeutics seller in Q3 2015 was LSV Asset Management, an estimated $195M sold.
Based on aggregated 13F filings for Q3 2015.